HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Marketers Exploiting Growing Probiotics Demand Warned About Disease, Anxiety Claims

Executive Summary

FDA warnings indicate marketers are looking to take advantage of growing demand for probiotics with disease treatment claims and also pitching herbal remedies to consumers to alleviate anxiety, depression and insomnia. New York firm offers OTC sales of injectable serums for skin toning. 

You may also be interested in...



Kyowa Hakko’s Immuse Paraprobiotic Works In Small Intestine For Immune Support

Kyowa Hakka offers Immuse paraprobiotic to activate the plasmacytoid dendritic cells in small intestine while most other probiotics work in large intestine. GOLO's Go-Digest supplement promotes healthy microflora in gut to support overall health.

COVID-19 Test Kit’s Use Of US FDA Logo With ‘Clinical Trial Number’ Fails Regulatory Test

Anytime COVID Test marketed home-use test without FDA approval or EUA and promoted it with an FDA logo and a “clinical trial number.” Warning letter says “your presentation conveys the misimpression that the product has been approved, cleared, authorized, endorsed or otherwise evaluated by FDA.”

Congressional Report Highlights Lack of Mandatory Supplement Listing As DSHEA 2.0 Talks Continue

The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.

UsernamePublicRestriction

Register

RS151505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel